United Therapeutics (NASDAQ:UTHR) COO Michael Benkowitz Sells 22,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $514.35, for a total transaction of $11,572,875.00. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Michael Benkowitz also recently made the following trade(s):

• On Monday, December 15th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $496.30, for a total transaction of $11,166,750.00.
• On Monday, December 8th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $478.58, for a total transaction of $10,768,050.00.
• On Monday, December 1st, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $479.91, for a total transaction of $10,797,975.00.
• On Monday, November 24th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $473.66, for a total transaction of $10,657,350.00.
• On Monday, November 17th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $470.43, for a total transaction of $10,584,675.00.
• On Monday, November 10th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $452.07, for a total value of $10,171,575.00.
• On Monday, November 3rd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $429.25, for a total value of $9,658,125.00.
• On Monday, October 27th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $417.50, for a total value of $9,393,750.00.
• On Monday, October 20th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $427.41, for a total value of $9,616,725.00.
• On Monday, October 13th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $440.35, for a total value of $9,907,875.00.

United Therapeutics Trading Down 0.8%

NASDAQ:UTHR traded down $4.26 during mid-day trading on Monday, reaching $502.90. 253,338 shares of the stock were exchanged, compared to its average volume of 577,139. The business has a fifty day moving average price of $471.38 and a 200 day moving average price of $388.59. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $519.99. The firm has a market capitalization of $21.65 billion, a PE ratio of 19.06, a PEG ratio of 5.04 and a beta of 0.86.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. The company had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. United Therapeutics’s revenue was up 6.8% on a year-over-year basis. During the same period in the prior year, the company earned $6.39 EPS. On average, sell-side analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have issued reports on UTHR. Jefferies Financial Group restated a “buy” rating and issued a $575.00 price target on shares of United Therapeutics in a research report on Wednesday, November 19th. HC Wainwright raised their price objective on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Bank of America upped their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research note on Tuesday, September 2nd. Oppenheimer raised their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a report on Friday, September 5th. Finally, Wells Fargo & Company boosted their price target on shares of United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a report on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $505.00.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of UTHR. Walleye Capital LLC lifted its position in shares of United Therapeutics by 23.4% in the first quarter. Walleye Capital LLC now owns 649 shares of the biotechnology company’s stock worth $200,000 after purchasing an additional 123 shares in the last quarter. CreativeOne Wealth LLC grew its position in United Therapeutics by 22.6% during the first quarter. CreativeOne Wealth LLC now owns 764 shares of the biotechnology company’s stock valued at $236,000 after purchasing an additional 141 shares in the last quarter. Trexquant Investment LP acquired a new position in United Therapeutics in the 1st quarter valued at approximately $2,749,000. WPG Advisers LLC acquired a new position in United Therapeutics in the 1st quarter valued at approximately $60,000. Finally, Vident Advisory LLC lifted its position in United Therapeutics by 45.2% in the 1st quarter. Vident Advisory LLC now owns 17,741 shares of the biotechnology company’s stock worth $5,469,000 after buying an additional 5,520 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.